Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$48.43M$48.43M+8.3% vs Q2 2019 Net Income-$26.07M-$26.07MN/M vs Q2 2019 EPS Diluted-$0.58-$0.58N/M vs Q2 2019 Operating Income-$23,111,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,763,000N/M Margins · derivedOperating margin-47.7%+34.0 pt vs Q2 2019
Net margin-53.8%+32.7 pt vs Q2 2019
ended Jun 30, 2020 · filed Jul 31, 2020 · 31 d after period end